1
|
Plourde L, Chang SL, Farzin H, Gagnon P, Hébert J, Foxman R, Deschamps P, Provost F, Masse-Grenier M, Stephan JF, Cheung K, Joly Y, Fallu JS, Dorval M. Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey. Palliat Med 2024; 38:272-278. [PMID: 38253521 PMCID: PMC10865753 DOI: 10.1177/02692163231222430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
BACKGROUND Internationally, there is a growing interest in the potential benefits of psilocybin-assisted therapy to treat existential distress at the end of life. However, the social acceptability of this therapy is not yet well known. AIM This study assesses the social acceptability of the medical use of psilocybin to treat existential distress at the end of life. DESIGN An online survey was conducted in Canada between November 23 and December 4, 2022. The questionnaire included items pertaining to perceptions, attitudes and concerns towards psilocybin-assisted therapy to treat existential distress at the end of life. PARTICIPANTS The sample (n = 2800) was stratified by province, age and sex. Participants were adults from four provinces of Canada: Québec, Ontario, Alberta and British Columbia. RESULTS Overall, 79.3% considered psilocybin-assisted therapy a reasonable medical choice for a patient suffering from existential distress at the end of life, 84.8% agreed that the public health system should cover the costs of the intervention and 63.3% would welcome the legalisation of psilocybin for medical purposes. Previous psilocybin use (p < 0.0001, for all dependent variables), exposure to palliative care (p < 0.05, for all dependent variables) and a progressive political orientation (p < 0.05, for all dependent variables) were associated with more favourable attitudes towards psilocybin-assisted therapy at the end of life. CONCLUSION The social acceptability of psilocybin-assisted therapy for existential distress at the end of life is rather high in Canada. These findings may contribute to efforts to mobilise resources and improve access to this emerging therapy in palliative and end of life care settings.
Collapse
Affiliation(s)
- Louis Plourde
- Faculty of Pharmacy, Université Laval, Québec City, QC, Canada
- CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada
| | - Sue-Ling Chang
- CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada
| | - Houman Farzin
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada
- Faculty of Medicine and Health Sciences, McGill University, Montréal, QC, Canada
| | - Pierre Gagnon
- CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada
- Faculty of Medicine, Université Laval, Québec City, QC, Canada
| | - Johanne Hébert
- Department of Health Sciences, UQAR, Lévis, Rimouski, QC, Canada
- CISSS of Chaudière-Appalaches Research Center, Lévis, QC, Canada
| | | | | | - François Provost
- CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada
- School of Psychology, Université Laval, QC, Canada
| | - Marianne Masse-Grenier
- Faculty of Pharmacy, Université Laval, Québec City, QC, Canada
- CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada
| | | | | | - Yann Joly
- Faculty of Medicine and Health Sciences, McGill University, Montréal, QC, Canada
- Centre of Genomics and Policy, McGill University, Montréal, QC, Canada
| | - Jean-Sébastien Fallu
- School of Psychoeducation, Université de Montréal, Montréal, QC, Canada
- Center for Public Health Research (CReSP), Montréal, QC, Canada
- Institut universitaire sur les dépendances (IUD), Montréal, QC, Canada
| | - Michel Dorval
- Faculty of Pharmacy, Université Laval, Québec City, QC, Canada
- CHU de Québec-Université Laval Research Center, Oncology Division, Québec City, QC, Canada
- CISSS of Chaudière-Appalaches Research Center, Lévis, QC, Canada
| | | |
Collapse
|